pGFP-C-shLenti vector lentiviral infection (green) . Scale bar = 20 μm. (B) Representative phase contrast images of GBM9-shcontrol and GBM9-shST8SIA3 [B] migrating cells (one experiment). Scale bar = 50 μm. Figure S2 . Suppression of A2B5 immunoreactivity in GBM6, GBM27, and GBM40 by neuraminidase impairs cell proliferation, migration, and clonogenicity (A)(B)(C) Dose-response cytotoxicity assays of neuraminidase were conducted for 72 h to assess the viability of GBM6, GBM27, and GBM40 cells grown as a 2D monolayer (n = 3). (D)(E)(F) Dose-response cytotoxicity assays of neuraminidase were conducted for 7 days to assess the viability of GBM6, GBM27, and GBM40 cells grown as 3D spheroids (n = 3). (G)(H)(I) GBM6, GBM27, and GBM40 spheroid areas were measured during the 7 days after neuraminidase treatment and normalized to Day 0. (J)(K)(L) Quantification of GBM6, GBM27, and GBM40 cell migration using the transwell assay after neuraminidase treatment at 0.125, 0.25, 0.5, or 1 U/mL for 6 h. The mean + SEM values of four independent experiments, each performed in duplicate, are shown. (M)(N)(O) The self-renewal capacity of GBM6, GBM27, and GBM40 was evaluated by limiting dilution assay in 96-well plates. The point cloud shows the percentage of spheres formed after 8 days of culture of cells treated or not with the respective EC50 neuraminidase dose. Non-parametric Wilcoxon-Mann-Whitney test shows * p < 0.05, ** p < 0.01. 
